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Summary 
Common chimpanzees (Pan  troglodytes) infected with hepatitis C  virus (HCV) show a disease 
progression similar to that observed for human patients. Although most infected animals  de- 
velop a chronic hepatitis, virus persistence is associated with an ongoing immune response, for 
which  the  beneficial  or  detrimental  effects are  uncertain.  Lines  of virus-specific  cytotoxic 
CD8 + T  lymphocytes (CTL) have been previously established from liver biopsies of two com- 
mon chimpanzees chronically infected with HCV-1. The viral epitopes recognized by six lines 
of CTL have been defined using synthetic peptides and shown to consist of 8 to 9-residue pep- 
tides derived from various viral proteins. Five of the epitopes derive from sequences that vary 
among strains  of HCV.  The majority of the  corresponding variant  epitopes from different 
HCV strains  were either recognized less efficiently or not at all by the CTL, suggesting their 
response may have limited potential for controlling replication of HCV variants. Complemen- 
tary DNAs encoding the class I alleles of the two common chimpanzees, Patr-A, -B, and -C 
were cloned, sequenced, and transfected individually into a class I-deficient human cell line. 
Analysis ofpeptide l~resentation by the class I transfectants to CTL identified the Parr class I al- 
lotypes that present the six epitopes defined here and an additional epitope defined previously. 
The assignment of epit~pes to class I aUotypes based upon analysis of the transfected cells corre- 
lates precisely with the segregation of antigen-presenting function within a panel of common 
chimpanzee cell lines and the expression of class I heavy chains as defined by isoelectric focus- 
ing. Five of the HCV-1 epitopes are presented by Patr-B aUotypes,  two epitopes are presented 
by a Patr-A allotypes, and none is presented by Patr-C allotypes. 
H 
epatitis C virus (HCV) 1 is the principal cause of com- 
munity-acquired and posttransfusion  non-A,  non-B 
hepatitis worldwide (1, 2). HCV is a small, enveloped, pos- 
itive-strand tkNA virus assigned to the family of Flaviviri- 
dae (3).  HCV causes  acute hepatitis and >50% of infected 
individuals  subsequently  develop  chronic  hepatitis  with 
10-20% eventually becoming cirrhotic (4). The pathogenic 
mechanisms that lead to the high rate of chronic liver dis- 
ease are poorly understood. CTL provide a beneficial im- 
mune response against  many viral infections (5),  but their 
role  in  HCV  infection  remains  unknown.  CD8 +  and 
CD4 +  CTL with specificity for HCV have been isolated 
from  the  livers  of persistently  infected individuals  (6-8). 
1Abbreviations used in this  paper: B-LCL,  B-lymphoblastoid  cell lines; ~2m, 
~2-microglobulin; HBV, hepatits B virus; HCV, hepatitis C virus; Patr-A, 
-B, -C, common chimpanzee P(~n troglodytes) A, B, and C locu.~ class I 
MHC antigens; W, vaccinia  virus. 
Uncertain is whether these CTL act beneficially to limit vi- 
ral  replication  or  exacerbate  tissue  damage  as  has  been 
shown for another hepatotropic virus, the hepatitis B virus 
(HBV) (9). 
Chimpanzees are the species most closely related to hu- 
mans and potentially the best animal model for the study of 
many diseases.  HCV  infection of chimpanzees leads  to  a 
course of disease  similar to  that seen for human patients. 
Most animals  (50-70%)  fail to resolve the  acute infection 
and  develop persistent or intermittent viremia after chal- 
lenge (10,  11). Chronicity results in necroinflammatory and 
ultrastructural changes in the liver that are like those typi- 
cally observed for humans chronically infected with HCV 
(12,  13). 
Kecently, we  initiated a prospective study of the  CTL 
response in common chimpanzees (Pan troglodytes) infected 
with the HCV-1  strain of virus. Several CD8 § CTL lines 
have  been  generated  from  liver-infiltrating  lymphocytes 
obtained from two  chronically infected chimpanzees and 
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vaccinia  viruses,  to  different  structural  and  nonstructural 
proteins  of HCV (14).  Despite  the presence of HCV-spe- 
cific  CD8 +  CTL,  infection  became  persistent  in  both 
chimpanzees. Subsequent study showed that a CTL epitope 
"fine mapped"  to amino acids  1446-1454 of the NS3 pro- 
tein of HCV-1  was mutated with  100% penetration  in all 
viral  isolates  derived  from the  fiver and serum  of one  in- 
fected  animal  (15).  This  observation  implies  viral  escape 
from CTL-mediated immunity might contribute to disease 
progression. 
CTL  of the  CD8 +  phenotype  typically recognize viral 
peptides  of 8-10  amino acids  in length  that  are  presented 
by MHC  class  I molecules  (16).  Analysis of CTL specific- 
ity, primarily in humans and mice,  has shown that the na- 
ture  of viral epitopes  presented  is  determined by substitu- 
tions within the peptide binding site that distinguish class I 
heavy chain allotypes (17). This property serves to diversify the 
CTL response within individuals of a population or species. 
The multigene family encoding class I heavy chains is in 
evolutionary terms,  highly dynamic  (18,  19).  Unlike most 
other  mammalian  species,  chimpanzees  have  class  I  genes 
that closely resemble  the  HLA class  I genes of humans.  In 
particular  the  highly  polymorphic  HLA-A,  -B,  and  -C 
genes which  are  most strongly implicated  in the  immune 
response have their orthologues Patr-A, -B, and -C in the 
common  chimpanzee  (Pan  troglodytes)  (20-24).  Indeed, 
there are no species-specific differences that distinguish  al- 
leles  of orthologous  human  and  chimpanzee  class  I  loci. 
Despite the similarities,  no individual class I allele is shared 
by the two species, although certain pairs of alleles,  particu- 
larly A locus alleles,  are very similar (25). 
As yet there is litde knowledge of the functional proper- 
ties of chimpanzee  class  I MHC  molecules  with which to 
complement  the  structural  comparisons.  The  two  chim- 
panzees  chronically infected  with  HCV,  and  from which 
various  CD8 + CTL fines  have  been  derived,  provided an 
opportunity  to  investigate  antigen  presentation  by  chim- 
panzee  class  I  molecules  during an immune  response  to a 
natural  pathogen of humans.  Furthermore,  such analysis is 
likely to provide  insight  as  to  the  role  of class  I  allotypes 
and CD8 §  CTL in disease progression and the desirability 
of  influencing  such  responses  through  vaccination.  To 
these ends we have defined the peptide epitopes recognized 
by  six  HCV-specific  CTL  lines  derived  from  the  two 
chronically infected chimpanzees and determined the iden- 
tities  and  primary structures  of the  autologous Patr class  I 
allotypes that present them. 
Materials and Methods 
Cell Lines.  Immortalized B-lymphoblastoid cell fines (B-LCL) 
were generated fi'om FicoU-Hypaque--separated chimpanzee PBMC 
by transformation with supernatant from the EBV-secreting mar- 
moset cell line B95-8 (American Type Culture Collection,  ILock- 
ville,  MD)  in  ILPMI  1640  medium  containing 20%  FCS  and 
1 Ixg/rrd  cyclosporin A  (Sandoz  ILesearch  Institute,  East  Han- 
over,  NJ)  as described  (14).  B  cell  lines  were grown in  ILPMI 
1640 medium (GIBCO BILL, Gaithersburg,  MD) supplemented 
with  10%  FCS  (Sigma  Chemical  Co.,  St.  Louis,  MO),  2  mM 
t-glutamine,  1.4 m/Vl sodium pyruvate, and 100 U/ml penicillin/ 
streptomycin (Irvine Scientific,  Santa Ana, CA). 
Virus-specific CTL Clones.  HCV-specific  CD8 + CTL fines were 
generated as described  previously (14). In summary, liver biopsies 
obtained using the modified Klatskin  technique  were  homoge- 
nized in PBS supplemented with  1% FCS.  CD8 + cells were iso- 
lated using anti-CD8 antibodies coupled to magnetic  beads (Dyna- 
beads;  Dynal  Inc.,  Great  Neck,  NY)  and  cloned  by  limiting 
dilution in 96-well round bottom plates containing irradiated  hu- 
man PBMC as feeder cells and in the presence of medium con- 
taining ILPMI  1640,  10%  FCS  heat-inactivated  FCS  (Hyclone 
Laboratories,  Inc.,  Logan,  UT),  50  U/ml  recombinant  human 
IL-2, 10% (vol/vol) IL-2 (Pharmacia,  Silver Springs, MD), antibi- 
otics, and 0.1 mg/ml anti-CD3 mAb (AMAC, Westbrook, ME). 
All CTL lines consisted  of >98% CD8 § cells as assessed by flow 
cytometry. HCV-specific CD8 + lines were maintained by peri- 
odic  restimulation  using anti-CD3  antibodies  in  medium  con- 
taining feeder cells. 
Cytotoxicity Assay.  CTL lines were tested for cytotoxic activ- 
ity  against  LCL  targets  and  transfectauts  using  a  standard  4-h 
Naz51CrO4 (SlCr) release assay (26). Target cells were prepared by 
incubating LCL with  synthetic peptides  (10 I.tg/ml unless  indi- 
cated  otherwise)  and 51Cr (50  ~Ci)  for  l  h  and  then  washing 
them three times. The radioactivity released during the 4-h incu- 
bation of CTL and target cells was measured from 100-1xl samples 
of culture supernatant and the percent specific lysis calculated  us- 
ing the formula:  100 X  [(experimental  cpm -  spontaneous  cpm)/ 
(total cpm -  spontaneous cpm)] =  % specific lysis. Spontaneous 
release was determined from targets  incubated in medium alone 
and  maximal  release  from  targets  incubated  with  5%  Triton 
X-100. CTL assays were replicated  with similar results. 
Peptides.  Peptides  were  synthesized  by  Chiron  mimotopes 
(Clayton, Australia) or ILesearch Genetics (Huntsville,  AL) using 
Fmoc  solid  phase  methods.  All  peptides  had  tree  NH,  and 
COOH termini. 
Cloning,  Sequencing, and Analysis of Patr Class I eDNA.  To- 
tal ILNA was prepared from 3  X  10  v LCL using RNAzol (Tel- 
Test,  Inc.,  Friendswood,  TX)  and  purified  as  described  (27). 
First-strand  eDNA was synthesized  using Moloney nmrine leuke- 
mia  virus  reverse  transcriptase  (GIBCO-BILL) according to the 
vendor's instructions.  Chimpanzee Patr class I cDNA was ampli- 
fied using the PCIL and oligonucleotide primers  (5' UT and ei- 
ther 3'  UTA, UTB, or UTC  depending upon the class I locus 
targeted)  that we have used routinely for the amplification  of hu- 
man HLA-A, -B, and -C alleles (28). The conditions were as de- 
scribed  (27) except the number of PCIL cycles was increased  to 
30.  The products were purified using the Wizard kit  (Promega 
Corp., Madison, WI) and subcloned into the replicative  form of 
the phage vectors M13mp18 and M13mp19.  Partial sequencing 
was performed manually using the Sequenase  kit (Sequenase  v2; 
United States Biochemical Co., Cleveland,  OH) and sequencing 
primers  $3/N3 and/or $4/N4 (28) in order to identify, and dis- 
tinguish  alleles. The sequence of selected  clones  was completed 
using a (model 373; Applied Biosystems,  Foster City, CA) DNA 
automated sequencer as described  (27). A consensus sequence was 
derived from the sequence of at least three clones. Analysis of the 
sequences  was performed using the GCG software  package  (Ge- 
netics Computer Group, Madison,  WI). Newly identified  Parr-A, 
-B, and -C alleles were named in accordance with the published 
guidelines  (29). 
Preparation of Class I Constructs for Transfection.  Class I  eDNA 
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synonymous substitutions were identified for certain Patr-A, -B, 
and -C alleles.  These inserts were removed from the replicative 
form of the M13 phage vector by digestion with Sail and HindlI! 
and subcloned into the dephosphorylated expression vector pBJ 1- 
neo (30) cut with Xhol and HindlIl. 
For those alleles for which all clones characterized had nonsyn- 
onymous substitutions, a strategy of splicing together the error- 
free segments from two imperfect clones was adopted. One of  the 
cDNA was cut out of the phage vector and ligated into dephos- 
phorylated pBluescript-KS(+) (Stratagene, LaJolla, CA) cut with 
Sail and  HindllI.  The  region  containing  PCK-induced  errors 
(one or a localized cluster of nucleotide substitutions) was then 
removed  by  digestion with  either  Sail  or  HindlII  (depending 
upon whether the 5' or 3' part of the insert was to be kept in the 
vector) and a restriction enzyme selected to cut once in the insert 
sequence and place all the errors in one of the two resulting frag- 
ments. The vector containing the error-free segment was isolated 
by gel purification using the BIO-10l kit (BIO 101 Inc., LaJolla, 
CA) and dephosphorylated with alkaline phosphatase (Boehringer 
Mannheim, Indianapolis, IN) according to Sambrook et al. (31). 
An  error-free  fragment  corresponding  to  the  region  removed 
from the first cDNA clone was isolated from the rephcative form 
of a second cDNA clone using the same restriction enzymes used 
to divide the first  insert. The  second fragment was  gel purified 
and ligated to the vector containing the first fragment using T4- 
DNA-Ligase (New England Biolabs, Inc., Beverly, MA)  as de- 
scribed (31).  The sequences of the recombinants thus produced 
were determined for the previously mutated regions. Clones hav- 
ing the correct sequence were subcloned into the expression vec- 
tor pBJl-neo as described above. 
Preparation and Characterization of Class I Transfectants.  The  HLA 
class I--deficient human B  cell line 721.221  (32)  was transfected 
with individual Patr-A, -B, or -C alleles cloned into the pBJ1- 
neo vector using the BTX electroporation system (BTX Inc., San 
Diego,  CA).  3  ￿  106  cells were resuspended in 200  I~1 of 1￿ 
HeBS  (20  mM  Hepes,  137  mM  NaC1,  5  mM  KCI,  0.7  mM 
Na2HPO4,  and  6  mM  dextrose) mixed with  20  ~g DNA  and 
electroporated in a 2-mm gap cuvette with a 350-V pulse at 360 
m~ and 50 I.LF  followed by a second pulse of the same duration 
after a 30-s pause. After resuspension in culture medium contain- 
ing 30% FCS, 106 aliquots of cells were transferred to the wells of 
a 24-well plate. 3 d later, medium containing G418 was added (1 
mg/ml active drug, GIBCO BRL). 
Cultures of G418 resistant cells were sorted on the basis of class 
I expression. Five million cells were incubated for 60 rain at 4~ 
with  fluorescein-conjugated W6/32  antibody,  which  binds  all 
human and chimpanzee class I allotypes (33). The cells were washed 
with sterile ice-cold PBS supplemented with 1 Ixg/ml propidium 
iodide (pl; Sigma Chemical Co.) and sorted using a FACStar  PLUs| 
flow cytometer (Becton Dickinson &  Co., San Jose, CA). Cul- 
tures developed from the sorted cells were used for analysis. 
Flow Cytometric  Analysis and Antibodies.  Surface expression of 
MHC class I molecules was determined by indirect immunofluo- 
rescence. Approximately 106  cells were  incubated with W6/32 
antibody at 4~  for 30 rain, washed with PBS, and then similarly 
incubated with fluoresceinated goat anti-mouse antibody (Bio- 
source  International,  Camafillo,  CA).  Cells were  washed  with 
PBS containing PI at a final concentration of 1 I~g/ml to facilitate 
the exclusion of dead cells. Analysis was performed using a FACS- 
can  |  flow cytometer (Becton Dickinson & Co.). Background flu- 
orescence was evaluated using an irrelevant isotype-matched first 
antibody (CVC.7)  (34).  Transfectants expressing human  class  I 
molecules were used as positive controls (35); for the analysis of 
transfectants  expressing chimpanzee  class  I  molecules,  untrans- 
fected 721.221  cells were used as the negative control. 
Immunoprecipitation and IEF.  lmmunoprecipitation  of class  I 
molecules and their analysis  by one-dimensional IEF gels were 
performed  as  described  (36).  Briefly,  LCL  or  transfected  cells 
were biosynthetically labeled with [3sS]Cys and [3sS]Met (Amer- 
sham Corp., Arlington Heights,  IL).  The  cells were lysed with 
detergent  and  the  lysates  were  precleared.  Chimpanzee  class  I 
molecules were immunoprecipitated using W6/32,  treated with 
Neuraminidase type VI (Sigma Chemical Co.), and analyzed on 
one-dimensional  IEF  gels  under  denaturing  conditions.  After 
electrophoresis, the gel was fixed in 15% acetic acid, treated with 
Amplify (Amersham Corp.), dried and exposed to Kodak XAR-5 
film (Eastman Kodak Co., Rochester, N30. 
EMBL/GenBank/DDBJAccession Numbers.  The accession num- 
bers for the Patr sequences cited in this paper are X13114  (Patr- 
A04),  U10540  (Patr-A11),  U10544  (Patr-A14),  X13115  (Patr- 
B01), U05586  (Parr-B13); the nucleotide sequences described in 
this report for Patr-A11, Patr-A14, Patr-B01, and Patr-B13 cover 
the complete coding region of these class l molecules and extend 
the previous entries. These  extended sequences and the  newly 
identified Patr sequences  (Patr-B16,  Parr-B17,  Patr-C03, Patr-C04, 
Patr-C05,  and Patr-C06)  have been submitted to  the  Genome 
Sequence  Data Base  (National Center  for  Genome  Resources, 
Santa Fe, NM) and will become available under the following ac- 
cession numbers: L47291  (Pat-r-All), L47292 (Patr-A14), L47293 
(Patr-B01),  L47297  (Patr-B13),  L47296  (Patr-B16),  L47348 
(Patr-B17),  L47294  (Patr-C03),  L47347  (Patr-C04),  L47298 
(Patr-C05), and L47299 (Parr-C06). 
Results 
CD8  + Cytotoxic  T  Cells from  the Livers of Chronically In- 
fected Chimpanzees Recognize HCV Peptides of Eight to Nine 
Amino Acid Residues in Length.  The goal of these first ex- 
periments was  to characterize the HCV-1  epitopes recog- 
nized by six HCV-l-specific cytotoxic CD8 +  T  cell lines 
established from  intrahepatic lymphocytes of two  chroni- 
cally infected chimpanzees. Using recombinant vaccinia vi- 
ruses (VV) as a source of antigen, previous analysis had lo- 
cahzed  the  epitopes  to  subsets  of viral proteins  (14).  We 
now  describe the use of synthetic peptides to define short 
peptide epitopes that serve as potent antigens in the sensiti- 
zation of autologous B  cell lines for CTL-mediated lysis. 
Two  CTL  lines  from  chimpanzee  Ch-458  (458/14B, 
458/5F)  and  one  from  chimpanzee  Ch-503  (503/11.3) 
were known to be specific for epitopes of either the E2 or 
NS2  proteins  that  localize  to  residues  364-906  of  the 
HCV-1  polyprotein (14). The specificity of CTL line 458/ 
14B was further analyzed by examining its capacity to lyse 
autologous B  cell targets sensitized with synthetic peptides 
representing  a  series  of overlapping 20-residue  sequences 
within residues 364-906  of HCV-1. As shown in Fig.  1 A, 
CTL  line 458/14B  recognized peptides p54  and p55  de- 
rived from residues 531-550 and 541-560, respectively. Ly- 
sis of target cells sensitized with peptides corresponding to 
the  flanking sequences  was  less e~cient and  peptides de- 
rived from other regions were inactive. These results indi- 
cate the target epitope for 458/14B  is contained in the se- 
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Figure  1.  Fine mapping ofCTL epitopes recognized by HCV-specific, chimpanzee class I-restricted CTL lines reveals epitopes contained in peptides 
of eight to nine amino acid residues length. The CTL lines 458/14B,  458/5F,  503/11.3,  458/12A,  503/13.4,  and 458/3H4  were previously broadly 
mapped with recombinant W  expressing core El, E2/NS1, NS2, and NS3 proteins (14).  Fine mapping was initially perfonrted by testing each line's 
ability to lyse autologous B-LCL targets individually incubated with overlapping synthetic peptides spanning the HCV antigens as identified with recom- 
binant W-infected targets (A,  C, E, G, and/). The epitope contained in the peptides (p54, p71, p206, and pl60) recognized by the individual clones 
(14B, 5F, 11.3, and 12A) was further mapped with a series ofsmaUer, overlapping peptides (not shown). Each peptide in a series was tested at a final con- 
centration of 10 p.g/ml. Those peptides giving the highest specific lysis were further truncated and tested over a range of concentrations as shown on each 
x-axis (B, D, F, H, and J). The E/T ratio shown is 20:1. 
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p55. A peptide corresponding to this sequence (p54A) was 
synthesized and shown to sensitize target cells for CTL rec- 
ognition over a range of concentrations (Fig.  1 B). A pep- 
tide  lacking the  NH2-terminal  asparagine  residue  (p54B) 
was equally potent, whereas removal of the COOH-termi- 
nal phenylalanine residue resulted in a peptide (p54D) that 
was somewhat less effective (Fig.  1 /3). These data suggest 
that the nonameric peptide p54B most hkely represents the 
epitope recognized by CTL line 458/14B, although further 
truncations of NH  2- and COOH-terminal residues will be 
required to estabhsh this point. 
The  set  of 20-residue  peptides  covering  amino  acids 
364-906  of HCV-1  was similarly used to characterize the 
epitope recognized by CTL hne 458/5F. Only the peptide 
corresponding to residues 701-720 (p71) stimulated lysis by 
this CTL hne (Fig.  1 C).  The epitope recognized by 458/ 
5F is therefore a product of the COOH-terminal region of 
the  E2  protein.  Further  definition  of the  epitope  was 
achieved by testing a series of overlapping 10-residue pep- 
tides spanning the sequence of p71.  Peptides p71E  (IAS- 
WAIKWEY) and p71F (SWAIKWEYVV) sensitized target 
cells for lysis, showing the epitope lies within their shared 
sequence (data not shown). Indeed, p71G a synthetic pep- 
tide  corresponding  to  this  octamer  sequence  (SWAIK- 
WEY) was  equally efficient for sensitization of target cells, 
indicating that  it  contained all  critical residues for class I 
MHC binding and T  ceil recognition (Fig.  1 D). 
The epitope recognized by CTL line 503/11.3 was ana- 
lyzed using synthetic 13-amino acid peptides encompassing 
residues 364-906 of HCV-1. The only active peptide was 
p206 (Fig.  1 E), which corresponds to residues 586-598, a 
part  of the  E2  protein  close  to,  but  distinct  from,  the 
epitope recognized by CTL line 458/14B.  Further defini- 
tion of the epitope was  obtained using synthetic peptides 
corresponding to  overlapping  10-residue sequences  span- 
ning  the  p206  sequence.  That  peptides  p206B  (RKHP- 
DATYSR) and p206C (KHPDATYSRC) sensitized target 
cells  for  lysis  by  CTL  line  503/11.3  (data  not  shown) 
pointed  to  the  epitope  being  their  shared  nonamer  se- 
quence. This thesis  was supported by analysis  of synthetic 
peptides corresponding to the nonamer sequence or to oc- 
tamer sequences in which either the NH2- or COOH-tenni- 
hal residues were missing:  the nonamer peptide (p206BC) 
was clearly nmst effective for target cell sensitization (Fig. 1 F-). 
Previous characterization of CTL line 458/12A showed 
that it recognizes an epitope within residues 907-1618  of 
the  HCV-1  NS3 protein  (14).  Individual  15-residue syn- 
thetic  peptides  derived from  the  sequence  of NS3  were 
used to further define the epitope. Two peptides (p159 and 
p160), which share the sequence of residues 1356-1367 of 
NS3,  sensitized  autologous  targets  for  lysis  by  458/12A 
(Fig.  1 G). When a series  of nonameric peptides offset by 
one residue that represented the overlap between peptides 
p159  and  p160  were  tested,  peptides  p160B  (VPHP- 
NIEEV)  and p 160D  (HPNIEEVAL) had activity whereas 
p 160C (PHPNIEEVA) and other peptides representing the 
flanking sequences did not  (data  not shown).  On titration 
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of the pl60B,  C, and D  peptides, the best sensitization of 
targets for killing was obtained with p160B (Fig.  1/-/). Fur- 
ther truncation of COOH-  or NH2-terminal residues  of 
p 160B abrogated target cell sensitization (data  not shown), 
and thus the minimum,  optimal epitope probably includes 
amino acids  1357-1365  of the NS3  protein.  That p160D 
also  has  activity might be due to  cross-reaction with this 
peptide, which also contains a residue identical to that ob- 
served in p160B, a proline, as putative position 2 anchor. 
The epitope recognized by CTL hne 503/13.4 was pre- 
viously mapped to either the core or E 1 proteins of HCV 
(14).  Analysis  of synthetic peptides  representing overlap- 
ping decamer sequences within the target region (residues 
1-340 of the polyprotein) revealed a single antigenically ac- 
tive peptide (p58, residues 234-243) (Fig.  1 /). Comparison 
of shorter synthetic peptides derived from the sequence of 
p58 identified the nonamer GNASRCWVA (p58D) as the 
minimal epitope for 503/13.4  (data  not shown).  Of note, 
this  epitope from the E1 protein overlaps with an octamer 
(ASRCWVAM)  presented by HLA-B35  to  CTL from a 
patient with chronic HCV (6). 
We  find  that  CTL line  458/3H4,  as  also  reported for 
CTL line 458/13F,  is  specific for an  epitope of the  NS3 
protein contained within the 15-residue peptide p189 (res- 
idues 1443-1457 of the HCV polyprotein) (14). Analysis of 
10-residue peptides derived from within the p189 sequence 
revealed  a  single  peptide  (p189.1:  GYTGDFDSVI)  with 
antigenic  activity  (data  not  shown).  A  related  nonamer 
peptide, which lacked the NHa-terminal glycine residue of 
p189.1, was found to be more potent than p189.1 (Fig. I J), 
whereas  peptides  lacking the  COOH-terminal  isoleucine 
or additional residues at the NH  2 terminus were inactive. 
Thus  the  minimum,  optimal  epitope  for CTL line  458/ 
3H4 appears to be the nonamer peptide YTGDFDSVI. 
This analysis of chimpanzee CD8 + CTL lines with spec- 
ificity for the HCV-1 strain of human HCV has identified 
six epitopes  derived from three  viral proteins.  A  seventh 
epitope  has  already  been  described  (14,  15).  Six  of the 
epitopes correspond to nonamer peptides and one to an oc- 
tamer (summarized in Table 1). The length ofpeptides rec- 
ognized  by  chimpanzee  CTL  are  thus  characteristic  of 
those presented by class I MHC molecules as defined from 
the study of humans and mice (37, 38). 
Correlation of Presentation of HCV-I  Epitopes with the Seg- 
regation of Class I  Heavy  Chain  Allotypes  in a Population of 
Common  Chimpanzees.  Identification of synthetic peptides 
corresponding to the HCV epitopes recognized by the CTL 
from chimpanzees Ch-458 and Ch-503, enabled us to cor- 
relate presentation of individual target epitopes with partic- 
ular MHC class I allotypes. The six CTL lines were tested for 
their  capacity  to  lyse  22  chimpanzee  EBV-transformed 
B-LCL, including 458LCL and 503LCL, in the presence of 
a n~xture ofpeptides representing the six epitopes (Fig. 2 A). 
Lytic reactions were then correlated with the presence of 
MHC class I heavy chains as revealed by isoelectric focusing 
gels of class I immunoprecipitates obtained from each cell line 
with the monomorphic antibody W6/32 (33) (Fig. 2 B). 
The pool ofpeptide epitopes sensitized cells of chimpan- Table  1.  Antigen Specificity and Restriction Elements of lntrahepatic CD8  + CTL Lines  from Ch-458 and Ch-503 
Peptide epitope 
CTL line  Antigenic protein  Name  Residues  Sequence  Restriction element 
458/5 F*  E2/NS 1'  p71G~  711-71811  SWAIKWEY~ 
458/14B  E2/NS 1  p 54B  542-550  TRPPLGNWF 
458/12A  NS3  p 160B  1357-1365  VPHPNIEEV 
458/3H4~  NS3  p189.2Y  1444--1452  YTGDFDSVI 
503/10D~  NS3  p189.2A  1446-1454  GDFDSVIDC 
503/13.4  E1  p58D  233-241  GNASRCWVA 
503/11.3  E2/NS1  p206BC  588-596  KHPDATYSR 
Patr-Al 1?** 
Patr-B 13 
Patr-B 13 
Patr-B01 
Patr-B 16 
Patr-B 16 
Patr-A04 
* Intrahepatic CD8 + CTL hnes from chimpanzees Ch-458 and Ch-503. 
*HCV-1 target protein. 
~Designation of the synthetic HCV peptide epitope. 
tl NH 2_ and COOH-terrmnal amino acids (aa) of the HCV-I peptide epitopes. 
￿82  amino acid sequence of the HCV-1 peptide epitopes. 
**The presentation ofp71H by Patr-A11 is based on exclusion as described in the text. 
**Clone 458/3H4 has the same specificity as clone 458/13F published previously (14) and was used throughout this study. 
%The mapping of the epitope recognized by line 503/10D has been described in Erickson et al. (14) and Weiner et al. (15). 
Figure 2.  Presentation ofHCV-1 peptide epitopes correlates with segregation of  class I heavy chain allotypes in a cohort of common chimpanzees. (A) 
Target cells  consisting of 20  allogeneic and 2  autologous EBV-transformed chimpanzee B-LCL  were pulsed with a pool of synthetic HCV peptide 
epitopes (p189.2, p206C, p71F, p160D, p54, and p189.2E) for 1 h  at the time ofSlCr labehng and tested against the CD8 + CTL lines 503/10D,  11.3; 
458/5F,  12A,  14B, and 3H4. The results are shown at an E/T ratio of 20:l and were regarded positive for a given target and CTL line if the specific lysis 
was ~>40% (indicated by +  in the matrix topping the gel, at the intersection ofa CTL row with the column of a target cell).  (B) One-dimensional IEF 
pattern of chimpanzee MHC class I molecules (Patr-A, -B, and -C) immunoprecipitated with mAb W6/32 from [3SS]methionine-labeled  cellular lysates of 
the same 22 chimpanzee B-LCL tested in the cytotoxicity assay. Significant lysis by a particular HCV-specific CD8 + CTL line was observed only for those 
cells that shared a baud(s) and therefore allele(s) in the IEF as indicated by the symbols (C), 0, II, 0, A, and IS]). Band (0) is only present in B-LCL from 
chimpanzee Ch-458, but is shared with B-LCL from chimpanzee Ch-335 not run on this gel, and 458LCL and 335LCL are both lysed by CD8 ~ CTL 
line 458/5F in the presence ofp71F as explained in the main text. (Arrow) lnvariant IB2m. NT, not tested. 
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rived in the expected manner. Thus 458LCL were lysed by 
CTL lines 458/5F,  458/12A,  458/14B,  and 458/3H4,  and 
503LCL were lysed by CTL lines 503/10D and 503/11.3. 
In addition, CTL line 503/11.3 lysed cells l~om Ch-458, sug- 
gesting chimpanzees Ch-458 and Ch-503 share a MHC class 
I allotype. Supporting this hypothesis was the finding that 
CTL line 503/11.3  lysed 6 of the 22 chimpanzee LCL in a 
pattern that correlated precisely with the presence of one of 
the class I heavy chain bands seen in the IEF gels.  The ex- 
ception was LCL from chimpanzee Ch-352.  This cell line 
has  a  class  I  heavy chain  band  with  the  same  isoelectric 
point  as  the  band  shared between  458LCL  and  503LCL, 
but was not lysed by CTL line 503/11.3.  This may be due 
to  the  expression by chimpanzee Ch-352  of a  distinct al- 
lele, which fortuitously has the same electrophoretic prop- 
erties as the allele common to Ch-458 and Ch-503 (Fig. 2). 
In a similar manner, class I heavy chain bands correlating 
with the presentation of all six of the HCV epitopes, were 
identified (Fig.  2). CTL lines 458/12A and 458/14B corre- 
lated  with  the  same  class  I  heavy chain  band,  suggesting 
their target epitopes are presented by the same MHC class I 
allotype.  CTL  line  458/5F  lysed  the  autologous  cell  line 
(458LCL)  but  no  other one  of the  22  chimpanzee  LCL. 
Analysis of EBV-transformed B  cell lines  from additional 
chimpanzees revealed a single allogeneic cell line (from chim- 
panzee Ch-335) that is lysed by CTL line 458/5F in the pres- 
ence of the peptide pool. Correlating with the pattern oflysis, 
cell lines 458LCL and 335LCL share a class I heavy chain 
band not seen in  the  other cell lines  (Fig.  2  and data not 
shown).  These  results  are  consistent  with  the  six  HCV 
epitopes being presented to CTL by MHC class I molecules 
and identify candidate class I allotypes for each epitope. 
Definition  of the MHC Class I Alleles ( Patr-A,  -B, and -C) 
Expressed by the Two Chimpanzees from which the HCV-specific 
Cytotoxic  T  Cell Lines  Were Derived.  To  define  the  chim- 
panzee class I allotypes that present the six HCV epitopes, 
we  cloned  and  sequenced  cDNA  encoding  the  classical 
MHC  class  I  alleles  from  the  two  chimpanzees  (Ch-458 
and Ch-503)  from which  the CTL were derived.  For the 
common chimpanzee the classical class I loci comprise Patr-A, 
Patr-B,  and  Patr-C  which  are  orthologous  to  the  human 
HLA-A,  -B,  and -C loci,  respectively. Both  chimpanzees 
are heterozygous for each locus, and cDNA corresponding 
to two Patr-A, -B, and -C alleles  were obtained from each 
animal  (Fig.  3).  These cDNA  gave  11  different sequences, 
one Patr-A allele being common to Ch-458 and Ch-503. 
The three Patr-A alleles  and two of the four Patr-B al- 
leles correspond to alleles  defined previously (21,  23,  24). 
The  four  Patr-C  sequences  and  two  of  the  Patr-B  se- 
quences  correspond  to  previously  undiscovered  alleles. 
One of the  "new"  Patr-B  alleles  (Patr-B17)  is distinctive, 
having various  amino  acid  substitutions  not  found  in  the 
known  chimpanzee  and  human  MHC  class  I  molecules. 
On  the  basis  of a  series  of linked  substitutions,  human 
HLA-C alleles  can be divided into two groups (39).  Three 
of the  Patr-C  alleles  (Patr-C03,  Patr-C05,  and  Patr-C06) 
are  similar  to  HLA-C  alleles  of one  group,  whereas  the 
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fourth allele (Patr-C04)  is similar to HLA-C alleles  of the 
second group. Thus, the division of C alleles into these two 
groups antedates separation of the human and chimpanzee 
lineages some 5 million years ago (40). 
Identification of the Chimpanzee Patr-A and -B Allotypes that 
Present Individual HC V Peptide Epitopes to CTL.  Comple- 
mentary DNA clones corresponding to the Parr-A, -B, and 
-C alleles  of chimpanzees Ch-458  and Ch-503  were sub- 
cloned into the eukaryotic expression vector pBJl-neo and 
transfected  into  the  class  1-deficient  human  B  cell  line 
721.221  (32).  In the  transfected  cells,  chimpanzee  class  I 
heavy chains associate with endogenous human 132-micro- 
globulin  (132m), which  is  identical  to  chimpanzee 132m in 
the amino acid sequence  (25).  Flow cytometric analysis  of 
the transfectants using the W6/32 m_Ab showed that 9 of the 
11  transfected alleles had levels of class I expression compa- 
rable  to  those  obtained  with  HLA  class  I  cDNA  clones 
(Fig.  4 A). No expression was obtained for cells transfected 
with two Patr-A alleles (Patr-A11 and Parr-A14 from chim- 
panzees Ch-458 and Ch-503, respectively)  which may be due 
to artefactual mutations in the cDNA clones (data not shown). 
The class I molecules expressed by the transfectants were 
immunoprecipitated and analyzed on IEF gels.  Each trans- 
fectant  expressed a  single  band  not  seen  in  untransfected 
721.221  cells, and their isoelectric points each corresponded 
to one of the  class I  heavy chain bands seen in either the 
"parental" EBV-transformed B  cell  line  from Ch-458  or 
Ch-503 (Fig. 4 B). This analysis, therefore, permitted assign- 
ment of alleles and sequences to the bands seen on IEF gels. 
The panel of nine transfected cell lines expressing single 
Parr class I alleles was tested for its capaci  W to present HCV 
peptide  epitopes  to  CTL.  CTL  specific  for  the  seven 
epitopes summarized in Table 1 were examined and for six 
of them, a single transfectant proved capable of presenting 
the target epitope (Fig. 5). Moreover, the transfectants were 
as active in presentation as the autologous B cell lines. One 
epitope was presented by a Patr-A allotype, the other five 
by Patr-B allotypes. No epitope was presented by Patr-C. 
CTL line 503/11.3 lyses both 458LCL and 503LCL cells 
for which the only shared class I allotype is Patr-A04. Con- 
sistent  with  these  observations, the  transfectant expressing 
Patr-A04  presented  peptide  p206BC  to  CTL  line  503/ 
11.3.  That the same subset ofautologous EBV-transformed 
chimpanzee  B  cell  lines  presented  peptides  p54  to  CTL 
458/14B  and peptides pl60D  to 458/12A  suggested these 
epitopes were presented by the same class I allotype.  This 
was  confirmed by demonstrating that  the  transfectant  ex- 
pressing Parr-B13 presented both epitopes to their respec- 
tive  CTL.  Similarly,  CTL  lines  503/13.4  and  503/10D 
were both demonstrated to recognize peptides presented by 
Patr-B16.  The  Patr-B0l  allotype  presented  the  relevant 
epitopic peptide  to  CTL line  458/3H4,  The  only,  Patr-B 
allotype that presented none of the epitopes studied here is 
the unusual Patr-B allele (Patr-B 17) of chimpanzee Ch-503 
(Table 1). For all CTL, the patterns of antigen presentation 
by the  transfectants confirmed the provisional assignments 
of antigen-presenting allotypes based on the panel analysis 
shown in Fig. 2. COIkSeIISUS 
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1768  Chimpanzee MHC Class Class I Presentation of Hepatitis C  Virus Figure 4.  (A) Cell surface expression of the mutant 721.221 LCL cell line transfected 
with cDNA encoding Patr-A, -B, and -C locus products from chimpanzees Ch-458 and 
Ch-503. Cells were stained with the anti-class I mAb W6/32 followed by a secondary 
FITC-coupled goat a  mouse antibody  and analyzed by flow cytometry.  Transfectants 
(Patr-AO4--Patr-C06)  are shown (e-n; solid histograms). For Patr-A04, the allele shared be- 
tween Ch-458  and Ch-503,  two independent transfectants, has been generated.  The 
positive controls  for antibody  binding were autologous  B-LCL  from chimpanzee  Ch- 
458 and Ch-503 (458LCL and 503LCL; a and b) and 721.22l  cells transfected with the 
human allele HLA-B*1501  and -B'4601  (c and d); the negative controls were untrans- 
fected 721.221  cells (open histogram). (B)  One-dimensional IEF  pattern  of individual 
chimpanzee Parr-A, -B, and -C molecules. Parr-A, -B, and -C molecules were immu- 
noprecipitated  from 3SS-labeled chimpanzee  class I  transfected 721.221  cells with the 
mAb  W6/32  (lanes Patr-AO4--Patr-C06  for  Ch-458  and  Ch-503  and  untransfected 
721.221 negative control). EBV-transformed B-LCL from the two chimpanzees used as 
source of  the alleles were run as positive controls (lanes B-LCL for Ch-458 and Ch-503). 
In each instance, a band is shared between a transfectant and the autologous cell, allow- 
ing an unambiguous assignment of the Patr-A, -B, and -C alleles to each baud observed 
in the immunoprecipitate  of the B-LCL from the two chimpanzees Ch-458 and Ch- 
503, respectively. (Arrow) Invariant 132m. 
None  of the  nine  transfectants presented peptide p71H 
to the 458/5F  CTL  hne.  By a  process of elimination, this 
result suggested the  Patr-A11  allotype,  for which a  trans- 
fectant was  not  available,  is  the  antigen-presenting mole- 
cule.  Supporting this  assignment is  correlation  of the  iso- 
electric  point  of Patr-A11,  calculated  on  the  basis  of the 
deduced amino  acid  sequence,  with  that  of the  observed 
heavy  chain  band  shared  by  the  cell  lines  (458LCL  and 
Figure 3.  Amino acid sequence predicted from the complete nucleotide sequence of  the Patr-A, -B, and -C alleles from chimpanzees Ch-458 and Ch- 
503 compared to the consensus sequence of all currently  identified HLA-A, -B, and -C alleles. Amino acids are indicated by single letter code. Differ- 
ences with the consensus are given by lowercase letter substitutions, whereas identity is indicated by a dash. Codon numbers are given above the consen- 
sus. The alleles are also tabulated in the box and have been denoted as new or with their recommended name (29), followed by the reference if already 
described m the literature. These sequence data are available from EMBL/GenBank/DDBJ  under the accession numbers as given in Materials and Methods. 
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Figure  5.  Lysis of chimpan- 
zee  MHC  class  I  transfected 
721.221  by  HCV-specific 
CD8 + CTL lines is peptide and 
allele specific. 721.221 cells ex- 
pressing single MHC class I alle- 
les  from  chimpanzees Ch-458 
(  Patr-A  04,  -BO1, -B13, -C03, 
and  -C04) and  Ch-503  (Patr- 
A04,  -BIG  -B17, -C05,  and 
-C06) were tested for lysis  by the 
CD8 + CTL lines 458/3H4,  14B, 
12A,  5F,  and  503/11.3,  13.4, 
10D in the presence (solid bars) or 
absence  (open bars) of cognate 
HCV-1 peptide epitope (p189.2Y, 
p54E,  p160D,  p71H, p206BC, 
p58D,  and p189.2A)  in  a  4-h 
SlCr-release  assay  at an E/T ratio 
of 20:1. The concentration of the 
HCV-1  peptides was  10  I~g/ml 
except  for  lines 503/13.4  and 
458/3H4, where a concentration 
of 100  I~g/rnl and 0.0l  I~g/ml 
HCV- l  peptide,  respectively, 
was  used. Each assay included 
autologous  targets from  chim- 
panzees Ch-458  and Ch-503  as 
positive  controls  and  untrans- 
fected 721.221 cells as negative 
controls. Note  that Ch-458  and 
Ch-503  share the A-allele Parr- 
A04. NT, not tested. 
335LCL) that present antigen to CTL line 458/5F. 
Natural  Variation  in  HCV-1  Epitopes  q(ten  Causes  Loss  of 
Recognition  by CD8 + CTL.  The  majority of epitopes de- 
fined  in  this  study  involve  sequences  that  vary  between 
strains of HCV. We therefore examined how natural varia- 
tion within these epitopes affected CTL recognition. Peptides 
having variant sequences  were  synthesized and  compared 
to  "wild-type"  HCV-1  peptide epitopes in their capacity 
to sensitize targets for lysis by the cognate CD8 + CTL line. 
Only  two  epitopes,  both  located  in  NS3,  were  con- 
served  in  all HCV  genotypes.  These  include  the  189.2A 
epitope  recognized  by  CTL  line  503/IOD,  which  was 
completely conserved  in  sequence  (15),  and  the  189.2Y 
epitope  recognized by  CTL  line  458/3H4,  which  shows 
variable  usage  of a  tyrosine  or  phenylalanine  residue  at 
amino acid position 1.  This variability in p189.2Y  did not 
affect recognition by CTL  line 458/3H4  (Fig. 6  E).  CTL 
503/11.3  recognized only one  of four  natural variants  of 
the E2  protein sequence.  Unknown  is whether the failure 
to recognize variants is due to poor binding of the variant 
peptides to class I, or poor recognition of the peptide-class 
I complex by CTL. The single amino acid substitution that 
distinguishes the  inactive variants  is  lysine for  arginine  at 
position 9  in  the  peptide  (Table  2).  However,  when  this 
substitution alone was introduced into the HCV-1  epitope, 
it caused no reduction in activity (Fig. 6 A). Thus, this sin- 
gle substitution cannot alone account for the lack of recog- 
nition of the three variant epitopes. Analogous results were 
obtained with  natural variants  of the  epitopes recognized 
by three other CTL. 2 of the 11 variants examined showed 
reduced antigenic activity and 8 gave no activity (Fig. 6, B-D). 
These results indicate naturally occurring variation in most 
epitopes  described  here  limits  cross-reactivity  of  class  I 
MHC-restricted CTL for other HCV subtypes. 
Discussion 
Investigation  of the  specificity of the  CD8 +  CTL  re- 
sponse  in  two  chimpanzees  chronically  infected  with 
HCV-1  provides further evidence suggesting that the host 
response of Pan troglodytes and Homo sapiens to HCV is sim- 
ilar. The seven CTL lines we studied were all specific for 8 
to 9-residue viral peptides presented by chimpanzee class l 
MHC  molecules.  With  few  exceptions  (41-43),  human 
CD8 +  CTL  are  directed  towards  peptide  epitopes  pre- 
sented by ailotypes of the HLA-A and B loci. For example, 
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Figure 6.  Effect  of natural sequence variation on recognition of HCV- 
specific CD8 + CTL Lines. Autologous  B-LCL  were sensitized with the 
indicated  concentration of the HCV-1  or variant epitopic peptide  and 
tested against the cognate CD8 § CTL line (A) 503/11.3;  (B) 458/14B; 
(C) 458/12A;  (D) 458/5F; and (E) 458/3H4 at an E/T ratio of 10:1. The 
HCV peptides were either minimum epitopes or contained the minimum 
epitope in their core sequence except for line 458/12A, where these resi- 
dues represented the suboptimal epitope p160D. The epitope represented 
by p206BC (R--)K) is a synthetic variant with a substitution ofa lysine for 
an arginine at the COOH terminus of the HCV-1 epitope p206BC. Lysis 
was measured in a standard 4-h 51Cr-release  assay and was always <5% for 
B-LCL treated with medium only. The sequence of the epitopes for the 
HCV  genotypes  (subtype  is  indicated  in  parentheses)  obtained  from 
Table 2.  HCV Subtype Spedficity  of CD8 + CTL Line 
503/11.3 
Percent specific 
lysis of targets at 
E/T ratio of 
HCV-strain 
Peptide  (subtype)  Sequence  40:1  10:1  2.5:1 
% 
None*  --~  --~  <111  <1  <1 
p206BC  HCV-1 (la)  KHPDATYSR  98  94  77 
p206BC1  HCV-H77(la)  KyPeATYSR  100  100  76 
p206BC2  HC-J6 (2a)  KHPD t TYi k  4  7  4 
p206BC3  HCV-JK1 (lb)  KHP e ATYt k  4  4  2 
p206BC4  HC-J8 (2b)  KHPDATYI  k  2  3  2 
*  Autologous EBV-transformed  B-LCL from chimpanzee Ch~503 were 
untreated or pulsed with 10 I~g/ml of synthetic peptide epitopes from 
wild-type or variant viruses for 1 h and tested against the p206BC-spe- 
cific CTL Line  503/11.3. 
HCV genotypes  and subtypes are according to the nomenclature of 
Simmonds et al. (63, 64). 
The sequence of HCV genotypes between aa 588-596 obtained from 
GenBank/EMBL/DDBJ database is shown in single letter code. p206 is 
the parental peptide.  Lower case letter indicates substitution. 
II Values represent percent specific 51Cr-release  in a 4-h assay. 
antigen  presentation  by  various  HLA-A  (A2,  A3,  All, 
A23, and A29) and HLA-B  (B7, B8, B35,  B44, B50, B51, 
and B53)  allotypes  has  stimulated a  CTL  response  in pa- 
tients infected persistently with HCV  (6, 7, 44-48). Chim- 
panzees  Ch-458  and  Ch-503  appear  to  have  similarly fo- 
cused  their  CD8 +  CTL  response  upon  HCV-1  peptides 
presented  by  allotypes  of Patr-A  and  -B  loci,  the  ortho- 
logues of HLA-A and HLA-B.  In neither species do  allo- 
types  of  the  orthologous  HLA-C  and  Patr-C  loci  seem 
prominent  in  stimulating T  cells.  HLA-C  is  effective  in 
regulating the  activities  of human  natural  killer cells  (49, 
50)  and similarities with  HLA-C  raise  the  possibility that 
Patr-C also performs this function. 
Five of the seven HCV-1  epitopes we  analyzed are pre- 
sented by Patr-B  allotypes.  This bias may be  the  result of 
sampling CTL from only two chimpanzees, and analysis of 
further animals is essential to see if dominance of HCV  an- 
tigen presentation by Patr-B  is  a  more  general phenome- 
non. Moreover, the potential for HCV to mutate and diver- 
sify within infected animals could result in CTL  responses 
to variant epitopes presented by Patr-A or C  allotypes that 
were invisible to screening assays using constructs and pep- 
tides derived from the wild-type HCV-1  sequence. 
EMBL/Genbank/DDBJ databases is shown in single letter code. Dashes 
represent  identity  with the pubhshed  HCV-1  sequence  (1)  and amino 
acid substitutions are indicated (63, 64). 
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is  worth  considering  the  possibility  that  Patr-B  allotypes 
may be better suited for HCV antigen presentation,  as has 
been recently proposed for the allo- and virus-specific CTL 
response in humans (51,  52).  Indeed, some of the strongest 
associations  of class  I  HLA with  disease  susceptibility are 
with alleles of HLA-B (53,  54).  The functional propensities 
of the HLA-A, -B, and -C loci can be correlated with dif- 
ferences in their polymorphism. By comparison to HLA-A 
or -C.  the HLA-B locus exhibits greater functional varia- 
tion between individual alleles,  a larger number of alleles, 
and a faster rate of generating new alleles (55-57). Although 
information  on  Patr-A,  -B,  and  -C  polymorphism is  less 
comprehensive than for HLA-A, -B, and -C, similar patterns 
are emerging for these chimpanzee class I loci (23,  25). 
Localization  of epitopes  within  the  envelope and  NS3 
proteins  of HCV-1  suggests  that  most  viral  proteins  are 
processed for class I MHC presentation.  Indeed,  the CTL 
lines described here were identified using only recombinant 
W  expressing  the  COOH-terminal  half  of  the  HCV 
polyprotein (14),  but more recent data indicate that other 
nonstructural  proteins such as NS4 are also recognized by 
intrahepatic  CTL from Ch-458  and Ch-503  (our unpub- 
lished observations). Thus, the epitopes defined here prob- 
ably represent a subset of those recognized by HCV-specific 
CTL from these animals.  Nevertheless, it is noteworthy that 
with the exception of two NS3  epitopes, naturally occur- 
ring variation among HCV subtypes limited cross-reactivity 
of HCV-1  (subtype la)-specific CTL lines.  This is likely to 
pose a challenge for control of multiple HCV types by vac- 
cine-induced CTL responses. Moreover, the limited ability 
of the  CTL lines  to  recognize  the  variant epitopes could 
explain in part the reoccurrence ofviremia and hepatitis in 
humans  (58)  and chimpanzees  (59-61)  after reexposure to 
other strains or subtypes of HCV. 
Another  consequence  of virus variation may be escape 
from CTL surveillance. Previous studies (15) demonstrated 
that  the  dominant  HCV  quasi-species  detected  in  chim- 
panzee Ch-503  contained a single amino acid substitution 
in the p189.2A epitope in NS3 that prevented recognition 
by CTL against the index peptide. The finding that naturally 
occurring variation in other epitopes reduces efficiency of 
CTL recognition suggests the potential for mutation in multi- 
pie epitopes that would facilitate persistence of the virus. 
Although  chimpanzees  Ch-458  and  Ch-503  share  the 
Patr-A04  allele,  we  have  only  been  able  to  detect  a  re- 
sponse to the E2 peptide p206BC presented by this allotype 
in animal Ch-503.  There are various possible explanations 
for this result, of which the most trivial is the failure to cul- 
ture  such  cells  from  the  tissue  of chimpanzee  Ch-458. 
More  interesting  is  the  possibility,  that  Ch-458  failed  to 
make a response, or that the tempo of the response was dif- 
ferent in the two animals. Future analysis  of the kinetics of 
the CD8 + CTL response during the course of an infection 
should address this issue and examine whether the apparent 
dominance of Patr-B presentation is a general feature of the 
chimpanzee  response  to  HCV  or  a  particular  feature  of 
chronic infection. 
Orthologous  chimpanzee and human MHC  class I loci 
are so alike that there are no shared "species-specific" fea- 
tures within the primary structures that permit the alleles of 
one species to be distinguished from those of the other spe- 
cies (25,  62).  Neither have any alleles shown to be identical 
in the  two species, a generalization that remains unaltered 
by the characterization in this study of six previously undis- 
covered Patr  class I  alleles.  Although  lineage  relationships 
can be discerned between  Patr-A and  HLA-A alleles,  and 
Patr-B and HLA-B alleles  share many of the same nmtifs, 
pairwise  comparison  of chimpanzee  and  human  allotypes 
always reveals differences within the peptide binding site.  It 
is therefore likely that in the details of their peptide binding 
specificity and of the precise HCV peptides presented,  in- 
dividual  chimpanzee allotypes will  in  general  not  show  a 
one-to-one correspondence with their most closely related 
human  allotypes.  Evidence  consistent  with  this  view  are 
the  differences in  the  HCV  peptides  presented  by HLA- 
A*0301  and  A*1101  and  the  related  chimpanzee  alleles, 
Patr-A04  and  Patr-All.  The  distinctions,  however,  are 
similar to those encountered when comparing HLA class I 
antigen presentation in different human populations or dif- 
ferent individuals.  Arguably,  both  the  similarities and  dif- 
ferences between class I HLA and Patr molecules contrib- 
ute  to  the  value  of chimpanzees  for  the  study  of HCV 
infection and of vaccination strategies aimed at diverse hu- 
man populations. 
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Note added in proq[." Since acceptance of this manuscript for publication, a transfected cell expressing the Patr- 
All allotype has been made. Incubation of this transfectant  with peptide p71H renders it susceptible to lysis 
by CTL 458/5F. This positive data confirms the conclusion, previously based on negative evidence (see Ta- 
ble I, Fig. 5, and associated text), that Patr-All presents peptides p71E, F, G, and H  (Fig. 1 D). 
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